Drug intelligence / Profile preview

diltiazem + verapamil

Development stage: Preclinical
Lead developer: Mitsubishi Tanabe Pharma
Modality: Small Molecules
Administration: Oral

Overview

A combination of two non-dihydropyridine calcium channel blockers used primarily for hypertension management. Both medications work by inhibiting calcium influx into cardiac and vascular smooth muscle cells during depolarization, resulting in vasodilation and reduced blood pressure. This combination may be considered for patients with a history of angioedema to ACE inhibitors or those at risk of hyperkalemia, though it requires careful monitoring due to potential interactions.

Targets

ADRA2A (α2A)KCNH2 (Voltage-gated potassium channel subfamily H member 2)CACNA1A (P-type Calcium Channel)ADRA1A (α1A)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)

Beyond the preview

Go deeper on diltiazem + verapamil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on diltiazem + verapamil.

Explore the full profile